Clinical Trial Search

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Percentage of Participants With Complete Response at Cystectomy or Ureterectomy Following Preoperative Dose Dense MVAC — 38 percentage of total participants

Primary: Complete Response Rate at 3 Months — 39 percentage of participants

Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…

Primary: Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate — 21 Participants

Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants

Primary: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0 — 0; 0.07 proportion of participants

Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants

Primary: Clinical Complete Response (CCR) Rate — 43 Percentage of participants

Primary: Proportion of Patients With Pathological Response — 26; 2 Participants

Primary: Median Overall Survival — 13.9 months

Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events

Primary: Pathologic Complete Response Rate — 9 Participants

Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants

Primary: Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care — 10.8; 2.5 Percentage of participants

Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)

Primary: Complete Response (CR) Rate in the Subset of Patients With Carcinoma in Situ (CIS) — 27 percentage of participants

Primary: Proportion of Participants With Complete Response (At 6 Months) — 0.5 proportion of participants

Primary: Number of Participants With Adverse Events — 2 Participants

Primary: The Pathologic Complete Response Rate (<pT0) of Neoadjuvant GCS Regimen in Patients With Muscle-invasive Bladder Cancer. — 6.67 percentage of participants

Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients

Primary: Overall Pathological Response Rate — 57.7 % of participants

Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects

Primary: Phase 1: Dose Limiting Toxicities (DLT) Following Intravesical Administration of ABI-009 — 0; 0; 0; 0 Participants

Primary: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib — -0.29; 0.128 fold change

Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants

Primary: Number of Patients Achieving Pathologic Response — 49 percentage of pathologic responders

Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab

Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants

Primary: Progression Free Survival — 8.2 months